Tempo Therapeutics Awarded $2.25 Million NIH SBIR Grant to Advance MAP™ Technology for Complex Wound Healing

Novel synthetic biomaterial is designed to support volumetric tissue regeneration while minimizing inflammatory foreign-body response SAN DIEGO, Sept. 23, 2026 /PRNewswire/ -- Tempo Therapeutics, Inc. ("Tempo"), a clinical-stage regenerative medicine company pioneering synthetic...